HUTCHMED (China) Ltd
fanregratinib
intrahepatic cholangiocarcinoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on fanregratinib for intrahepatic cholangiocarcinoma is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 15h ago
“Supported by data from the study, a New Drug Application (NDA) for fanregratinib for the treatment of adult patients with advanced, metastatic or unresectable ICC with fibroblast growth factor receptor (“FGFR”) 2 fusion/rearrangement who ha”